Detalhe da pesquisa
1.
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood
; 2024 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754055
2.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Hematol Oncol
; 40(1): 22-30, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713465
3.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Blood
; 128(14): 1814-1820, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354719
4.
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
Haematologica
; 107(3): 740-743, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788983
5.
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
Blood
; 124(8): 1288-95, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859361
6.
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
Haematologica
; 103(11): e541-e543, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794145
7.
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation.
Blood Adv
; 7(5): 866-874, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973196
8.
Secondary malignancies among mantle cell lymphoma patients.
Eur J Cancer
; 195: 113403, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952281
9.
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project.
Hemasphere
; 7(8): e928, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37529083
10.
Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival.
Blood Adv
; 5(6): 1638-1647, 2021 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33710334
11.
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.
Exp Hematol Oncol
; 8: 16, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31406628